Abstract
To date, the clinical pharmacology of large intravenous doses of azithromycin has not been described. In the present study, single 2-h intravenous infusions of 1, 2, and 4 g of azithromycin were administered to three parallel groups (in each group, six received active drug and two received placebo) of healthy male subjects. Toleration (assessed by scores of subject-administered visual analog scale tests spanning 0 [good] to 10 [poor]), safety, pharmacokinetics, and serum motilin levels were monitored for up to 240 h after the start of each intravenous infusion. Mean nausea scores of 0.0, 0.0, 1.0, and 0.5 and abdominal cramping scores of 0.0, 0.0, 0.4, and 0.4 for 12-h periods after doses of 0, 1, 2, and 4 g of azithromycin, respectively, suggested that azithromycin was well tolerated. Because of the standardized 1-mg/ml infusates, all subjects in the 4-g dosing group complained of an urgent need to urinate. There were no consistent trends in endogenous motilin levels throughout the study. The maximum concentration of azithromycin in serum (10 micrograms/ml after a 4-g dose) and the area under the concentration-time curve (82 micrograms.h/ml after a 4-g dose) were dose related. The mean pharmacokinetic parameters were an elimination half-life of 69 h, total systemic clearance of 10 ml/min/kg, and a volume of distribution at steady state of 33.3 liters/kg. The pharmacokinetic results suggest that the long half-life of azithromycin is due to extensive uptake and slow release of the drug from tissues rather than an inability to clear the drug. Single intravenous doses of up to 4 g of azithromycin in healthy subjects are generally well tolerated, and quantifiable concentrations may persist in serum for 10 days or more.
Full Text
The Full Text of this article is available as a PDF (202.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barry A. L., Jones R. N. Interpretative criteria for the agar diffusion susceptibility test with azithromycin. J Antimicrob Chemother. 1988 Nov;22(5):637–641. doi: 10.1093/jac/22.5.637. [DOI] [PubMed] [Google Scholar]
- Barry A. L., Jones R. N., Thornsberry C. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob Agents Chemother. 1988 May;32(5):752–754. doi: 10.1128/aac.32.5.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bergan T., Jørgensen N. P., Olszewski W., Zhang Y. Azithromycin pharmacokinetics and penetration to lymph. Scand J Infect Dis Suppl. 1992;83:15–21. [PubMed] [Google Scholar]
- Coates P., Daniel R., Houston A. C., Antrobus J. H., Taylor T. An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers. Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):850–852. doi: 10.1007/BF01975839. [DOI] [PubMed] [Google Scholar]
- Foulds G., Shepard R. M., Johnson R. B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):73–82. doi: 10.1093/jac/25.suppl_a.73. [DOI] [PubMed] [Google Scholar]
- Itoh Z., Nakaya M., Suzuki T., Arai H., Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol. 1984 Dec;247(6 Pt 1):G688–G694. doi: 10.1152/ajpgi.1984.247.6.G688. [DOI] [PubMed] [Google Scholar]
- Ives D. V., Davis R. B., Currier J. S. Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. AIDS. 1995 Mar;9(3):261–266. [PubMed] [Google Scholar]
- Kissinger P., Clark R., Morse A., Brandon W. Comparison of multiple drug therapy regimens for HIV-related disseminated Mycobacterium avium complex disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jun 1;9(2):133–137. doi: 10.1097/00042560-199506000-00005. [DOI] [PubMed] [Google Scholar]
- Lalak N. J., Morris D. L. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet. 1993 Nov;25(5):370–374. doi: 10.2165/00003088-199325050-00003. [DOI] [PubMed] [Google Scholar]
- Mitznegg P., Bloom S. R., Christofides N., Besterman H., Domschke W., Domschke S., Wünsch E., Demling L. Release of motilin in man. Scand J Gastroenterol Suppl. 1976;39:53–56. [PubMed] [Google Scholar]
- Peeters T. L., Vantrappen G., Janssens J. Fasting plasma motilin levels are related to the interdigestive motility complex. Gastroenterology. 1980 Oct;79(4):716–719. [PubMed] [Google Scholar]
- Peeters T., Matthijs G., Depoortere I., Cachet T., Hoogmartens J., Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol. 1989 Sep;257(3 Pt 1):G470–G474. doi: 10.1152/ajpgi.1989.257.3.G470. [DOI] [PubMed] [Google Scholar]
- Shepard R. M., Duthu G. S., Ferraina R. A., Mullins M. A. High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues. J Chromatogr. 1991 Apr 19;565(1-2):321–337. doi: 10.1016/0378-4347(91)80393-q. [DOI] [PubMed] [Google Scholar]
- Tomomasa T., Kuroume T., Arai H., Wakabayashi K., Itoh Z. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci. 1986 Feb;31(2):157–161. doi: 10.1007/BF01300701. [DOI] [PubMed] [Google Scholar]
- Whitman M. S., Tunkel A. R. Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect Control Hosp Epidemiol. 1992 Jun;13(6):357–368. doi: 10.1086/646545. [DOI] [PubMed] [Google Scholar]
- You C. H., Chey W. Y., Lee K. Y. Studies on plasma motilin concentration and interdigestive motility of the duodenum in humans. Gastroenterology. 1980 Jul;79(1):62–66. [PubMed] [Google Scholar]
- Zuckerman J. M., Kaye K. M. The newer macrolides. Azithromycin and clarithromycin. Infect Dis Clin North Am. 1995 Sep;9(3):731–745. [PubMed] [Google Scholar]